Valeant Pharmaceuticals (VRX.TO) 160.42 $VRX.TO
Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation
PR Newswire - Tue Nov 18, 7:00AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Ideal Implant Incorporated today announced the receipt of approval from the U.S. Food and Drug Administration (FDA) and Health Canada to market the IDEAL IMPLANT® Saline-filled Breast Implant for use in primary breast augmentation or replacement of existing augmentation implants. The FDA approval of the IDEAL IMPLANT was based on an extensive review of various studies and data including a U.S. clinical trial that began in 2009 with 45 plastic surgeons and 502 women, who underwent breast augmentation or replacement of augmentation implants. The clinical trial is on-going and will continue to provide follow-up data through 2020.
VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Business Highlights
By The Associated Press - AP - Mon Nov 17, 4:57PM CST
___
VRX: 141.94 (+5.21), HAL: 48.54 (-0.69), GOOGL: 544.51 (-2.13), GOOG: 535.03 (-1.48), NRG: 31.74 (+0.06), VRX.TO: 160.42 (+6.02)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 213.37 (+4.17), ACT: 269.60 (+21.66), VRX: 141.94 (+5.21), MRK: 59.89 (+0.43), VRX.TO: 160.42 (+6.02)
Valeant Comments On Allergan Announcement
PR Newswire - Mon Nov 17, 8:29AM CST
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 213.37 (+4.17), ACT: 269.60 (+21.66), VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Physicians Continue to Voice Strong Support for Allergan via Open Letters to the Eye Care Community
Business Wire - Fri Nov 14, 8:00AM CST
Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company"
today announced results from a recent survey of eye care professionals and the availability of an open letter website in response to requests from physician customers for a platform to voice their concerns regarding the unsolicited proposal from Valeant Pharmaceuticals International, Inc. ("Valeant" to acquire Allergan.
AGN: 213.37 (+4.17), VRX.TO: 160.42 (+6.02)
Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey
CNW Group - Thu Nov 13, 4:00PM CST
Expansion of its U.S. headquarters solidifies commitment to grow jobs and support the local economy
VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 10.01 (+0.18), TEVA: 57.23 (-0.01), ASPX: 25.15 (+0.31), GSK: 46.28 (+0.40), PRAN: 1.65 (-0.03), VRX.TO: 160.42 (+6.02)
Valeant Pharmaceuticals Sends Letter To Physician Customers
CNW Group - Fri Nov 07, 4:00PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today sent a letter to physician customers in order to address misconceptions and clarify how Valeant operates its business.
VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Allergan deal inches forward with court's decision
By The Associated Press - AP - Tue Nov 04, 3:59PM CST
In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting.
VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Valeant And Pershing Square May Vote At Special Meeting
CNW Group - Tue Nov 04, 12:27PM CST
Today, the United States District Court for the Central District of California held that Pershing Square Capital Management, L.P., Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and related parties may vote shares of Allergan, Inc. (NYSE: AGN) or proxies at the upcoming December 18 stockholder meeting. Allergan had sought to disenfranchise its largest shareholder, PS Fund 1, along with other shareholders solicited by PS Fund 1, by seeking an injunction to prevent them from voting at Allergan's December 18 special meeting. Today's ruling by Judge David O. Carter means that all Allergan shareholders, including PS Fund 1, will be permitted to have their voices heard by voting at the special meeting.
AGN: 213.37 (+4.17), VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Valeant: We'll bump Allergan offer to $200 a share
By The Associated Press - AP - Mon Oct 27, 10:14AM CDT
The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent, which would mean $200 or more per share for the maker of Botox.
AGN: 213.37 (+4.17), VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Valeant Delivers Letter To Allergan Board
CNW Group - Mon Oct 27, 5:55AM CDT
· Prepared to Improve Offer And Provide Value of at Least $200 a Share
AGN: 213.37 (+4.17), VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
New Solution for Patients, Quarterly Financial Results, Clinical Study Initiation, Merger Updates, and Product Launch - Research Reports on CVS, Valeant, Regeneron, Allergan and Agilent
PR Newswire - Thu Oct 23, 8:20AM CDT
Today, Analysts Review released its research reports regarding CVS Health Corporation (NYSE: CVS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Allergan Inc. (NYSE: AGN) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7418-100free.
AGN: 213.37 (+4.17), VRX: 141.94 (+5.21), A: 40.80 (-0.44), CVS: 90.12 (unch), REGN: 413.22 (+13.57), VRX.TO: 160.42 (+6.02)
Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Oct 20, 6:00AM CDT
-- 2014 Third Quarter Results
VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation
PR Newswire - Tue Nov 18, 7:00AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Ideal Implant Incorporated today announced the receipt of approval from the U.S. Food and Drug Administration (FDA) and Health Canada to market the IDEAL IMPLANT® Saline-filled Breast Implant for use in primary breast augmentation or replacement of existing augmentation implants. The FDA approval of the IDEAL IMPLANT was based on an extensive review of various studies and data including a U.S. clinical trial that began in 2009 with 45 plastic surgeons and 502 women, who underwent breast augmentation or replacement of augmentation implants. The clinical trial is on-going and will continue to provide follow-up data through 2020.
VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Business Highlights
By The Associated Press - AP - Mon Nov 17, 4:57PM CST
___
VRX: 141.94 (+5.21), HAL: 48.54 (-0.69), GOOGL: 544.51 (-2.13), GOOG: 535.03 (-1.48), NRG: 31.74 (+0.06), VRX.TO: 160.42 (+6.02)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 213.37 (+4.17), ACT: 269.60 (+21.66), VRX: 141.94 (+5.21), MRK: 59.89 (+0.43), VRX.TO: 160.42 (+6.02)
Valeant Comments On Allergan Announcement
PR Newswire - Mon Nov 17, 8:29AM CST
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 213.37 (+4.17), ACT: 269.60 (+21.66), VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Physicians Continue to Voice Strong Support for Allergan via Open Letters to the Eye Care Community
Business Wire - Fri Nov 14, 8:00AM CST
Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company"
today announced results from a recent survey of eye care professionals and the availability of an open letter website in response to requests from physician customers for a platform to voice their concerns regarding the unsolicited proposal from Valeant Pharmaceuticals International, Inc. ("Valeant" to acquire Allergan. AGN: 213.37 (+4.17), VRX.TO: 160.42 (+6.02)
Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey
CNW Group - Thu Nov 13, 4:00PM CST
Expansion of its U.S. headquarters solidifies commitment to grow jobs and support the local economy
VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 10.01 (+0.18), TEVA: 57.23 (-0.01), ASPX: 25.15 (+0.31), GSK: 46.28 (+0.40), PRAN: 1.65 (-0.03), VRX.TO: 160.42 (+6.02)
Valeant Pharmaceuticals Sends Letter To Physician Customers
CNW Group - Fri Nov 07, 4:00PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today sent a letter to physician customers in order to address misconceptions and clarify how Valeant operates its business.
VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Allergan deal inches forward with court's decision
By The Associated Press - AP - Tue Nov 04, 3:59PM CST
In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting.
VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Valeant And Pershing Square May Vote At Special Meeting
CNW Group - Tue Nov 04, 12:27PM CST
Today, the United States District Court for the Central District of California held that Pershing Square Capital Management, L.P., Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and related parties may vote shares of Allergan, Inc. (NYSE: AGN) or proxies at the upcoming December 18 stockholder meeting. Allergan had sought to disenfranchise its largest shareholder, PS Fund 1, along with other shareholders solicited by PS Fund 1, by seeking an injunction to prevent them from voting at Allergan's December 18 special meeting. Today's ruling by Judge David O. Carter means that all Allergan shareholders, including PS Fund 1, will be permitted to have their voices heard by voting at the special meeting.
AGN: 213.37 (+4.17), VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Valeant: We'll bump Allergan offer to $200 a share
By The Associated Press - AP - Mon Oct 27, 10:14AM CDT
The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent, which would mean $200 or more per share for the maker of Botox.
AGN: 213.37 (+4.17), VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
Valeant Delivers Letter To Allergan Board
CNW Group - Mon Oct 27, 5:55AM CDT
· Prepared to Improve Offer And Provide Value of at Least $200 a Share
AGN: 213.37 (+4.17), VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
New Solution for Patients, Quarterly Financial Results, Clinical Study Initiation, Merger Updates, and Product Launch - Research Reports on CVS, Valeant, Regeneron, Allergan and Agilent
PR Newswire - Thu Oct 23, 8:20AM CDT
Today, Analysts Review released its research reports regarding CVS Health Corporation (NYSE: CVS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Allergan Inc. (NYSE: AGN) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7418-100free.
AGN: 213.37 (+4.17), VRX: 141.94 (+5.21), A: 40.80 (-0.44), CVS: 90.12 (unch), REGN: 413.22 (+13.57), VRX.TO: 160.42 (+6.02)
Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Oct 20, 6:00AM CDT
-- 2014 Third Quarter Results
VRX: 141.94 (+5.21), VRX.TO: 160.42 (+6.02)
